Skip to content

Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias

Endoscopic Submucosal Dissection Versus Local Laparoscopic Surgical Resection (Transanal Minimally Invasive Surgery [TAMIS] / Transanal Endoscopic Operation [TEO]) In Early Rectal Neoplasias. Multicentric and Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03959839
Acronym
DSETAMIS2018
Enrollment
70
Registered
2019-05-22
Start date
2019-04-01
Completion date
2024-12-20
Last updated
2025-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Neoplasms

Keywords

Early Rectal Neoplasms, ESD, TAMIS, TEO, Recurrence, R0, Safety

Brief summary

A multicenter non-inferiority randomized clinical trial to compare Endoscopic treatment (ESD) and Minimally Invasive Laparoscopic Local Surgical Treatment (TAMIS or TEO) for early rectal neoplastic lesions (adenoma & T1CRC) Primary aim: To compare the long-term local recurrence rate (12 months after the procedure) Secondary aims: Compare en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate, safety (rate of complications), morbidity and cost-effectiveness analyses.

Detailed description

A multicenter non-inferiority randomized clinical trial is proposed to compare two types of treatment for early rectal neoplastic lesions. Study arms: 1. Endoscopic treatment: Endoscopic Submucosal Dissection (ESD) 2. Minimally invasive laparoscopic local surgical treatment: Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO). Aims: Primary aim: To compare the long-term local recurrence rate (12 months after the procedure) of rectal lesions after ESD vs Surgical treatment (TAMIS/TEO). Secondary aims: Both arms of the study are compared according to other efficacy-related variables (en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate \[6 months\]), safety (rate of complications), morbidity (comparing different specific indexes: Wexner index, EQ-5L-5D, etc) and cost-effectiveness analyses (QALY). Inclusion criteria: * Patients older than 18 y/o * Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in diameter. * The edges of the lesion should be more than 3 cm from the external anal margin and up to 14 cm from it. * Circumferential involvement \<50% Exclusion criteria: * Patients who refuse to participate. * Diagnosis of inflammatory bowel disease with rectal involvement. * Pregnant. * Anorectal fibrosis due to previous anorectal surgery. * Lateral Spreading Lesions (LST classification) Granular Homogeneous type * Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi superficial pattern). * Rectal lesions of any size with high suspicion of deep submucosal invasion or locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn crypt pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal EUS/Pelvic MRI) * Existence of synchronous colorectal lesions that require other surgical treatment in any case. N-size estimation: Assuming a global rate of long-term local recurrence in rectal lesions treated by TAMIS/TEO or ESD of 2.5% (using the data available in the medical literature), considering a non-inferiority limit of 10%, power of 80% (Beta error 0.2, alpha error 0.05) and assuming a loss of patients during the follow-up around 10%, 34 patients per group are required. Follow-up and Information collect: The follow-up will be of 1 year from the date of the intervention and the visits in which the information to be analyzed will be collected are adjusted to the usual clinical practice. The data would be registered using the on-line database system for medical research RedCap. Other information: The entire protocol of this study has been approved by de Ethical Committee on Clinical Research of the Puerta de Hierro University Hospital. The study counts with a Civil Responsibility Insurance policy.

Interventions

PROCEDUREESD

Rectal Endoscopic Submucosal Dissection

PROCEDURETAMIS

Transanal Minimally Invasive Surgery

PROCEDURETEO

Transanal Endoscopic Operation

Sponsors

Spanish Society of Digestive Endoscopy
CollaboratorOTHER
Dr. Alberto Herreros de Tejada Echanojáuregui
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients older than 18 y/o * Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in diameter. * The edges of the lesion should be more than 3 cm from the external anal margin and up to 14 cm from it. * Circumferential involvement \<50%

Exclusion criteria

* Patients who refuse to participate. * Diagnosis of inflammatory bowel disease with rectal involvement. * Pregnant. * Anorectal fibrosis due to previous anorectal surgery. * Lateral Spreading Lesions (LST classification) Granular Homogeneous type * Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi superficial pattern). * Rectal lesions of any size with high suspicion of deep submucosal invasion or locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn pit pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal EUS/Pelvic MRI) * Existence of synchronous colorectal lesions that require other surgical treatment in any case.

Design outcomes

Primary

MeasureTime frameDescription
local recurrence rate12 monthspresence of remaining neoplastic tissue in resection site

Secondary

MeasureTime frameDescription
Short-term local recurrence rate6 monthsPresence of remaining neoplastic tissue in resection site
Morbidity12 monthsChanges in patients' quality of life using validated scores (both, specific and non-specific)
En-bloq resection rate1 hourSingle piece of resection specimen
R0 resection rate1 hourFree margin of neoplastic tissue both laterally and deep
Cost-effectiveness analyses (QALY)12 monthsCost-effectiveness analyses usin QALYs
Length of hospital stay1 hourDays of hospital stay
Early complications rate1 hourRegistration of any deviations on the normal postoperative period in the first 24 hours
Delayed complications rate1 hourRegistration of any deviations on the normal postoperative period after the first 24 hours and up to 30 days after the procedure
Time per procedure1 hourThe length of the procedure expressed in minutes

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026